glp-1compoundpharmacy

The formulation archive
Independent editorial information · not individual medical advice

Commercial pages may contain paid referral links. Compare the full payment terms and licensed-care details before enrollment.

This page contains affiliate links. We may earn a commission if you sign up through them, at no cost to you. All recommendations are independent.

The New "Prescriber Notes" Requirement: What Personalization Actually Looks Like on Your Rx

Post-ruling, prescriber notes on compounded GLP-1 prescriptions have gotten longer and more specific. Here's what those notes actually contain, why the language matters, and how to read your own prescription record.

What Changed

Before mid-2025, a compounded semaglutide prescription might have been as sparse as: "Compounded semaglutide 2.5 mg/mL, inject weekly, quantity 3 vials." Post-ruling, that same prescription now typically carries a paragraph of prescriber notes documenting the personalization basis for compounding.

The change wasn't cosmetic. Regulators clarified that a 503A compounded product needs a documented, patient-specific clinical basis — and prescribers responded by writing those bases explicitly into the Rx record.

What Personalization Notes Actually Contain

Modern prescriber notes on compounded GLP-1 prescriptions typically address at least one of the following:

Embody

Injectable semaglutide — pricing varies

Injectable semaglutide only; a lead compounded-injectable option.

  • Injectable semaglutide focus
  • Standard 12-week titration
  • Direct-to-patient pharmacy shipping
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →
Sponsored partner · Weight-management telehealthOak GLP-1

Review current treatment pathways, screening and follow-up, and clarify which medication and monthly charges apply.

Explore Oak GLP-1 ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.

How to Read Your Own Prescription

Most telehealth platforms give patients access to their prescription details through the patient portal. Look for the section labeled "prescriber notes," "clinical rationale," or "compounding basis." It should identify at least one of the personalization categories above with specific reference to your intake information.

If your prescription doesn't include such notes, or if the notes are boilerplate language that could apply to any patient, that's a signal worth raising with the platform's care team. Well-run platforms will document properly on request.

Sponsored partner · Weight-management telehealthOak GLP-1

Review current treatment pathways, screening and follow-up, and clarify which medication and monthly charges apply.

Explore Oak GLP-1 ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.
SPONSORED CARE OPTION

Sesame

Compare licensed-clinician services and ask about pharmacy sourcing, FDA-approved treatment options and itemized charges. Compounded medicines are not FDA-approved.

Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.

Explore Sesame program ↗

Why the Documentation Matters to You

Two practical reasons. First, if your pharmacy is audited or receives a regulatory inquiry, documented personalization is what makes your prescription defensible. A pharmacy with well-documented Rx records is less likely to face disruption. Second, if you switch pharmacies later, the personalization documentation carries with you — the new pharmacy can honor the same clinical basis rather than requiring an entirely new evaluation.

MadeMed

Oral tirzepatide ~$229/mo

Independent compounder offering compounded oral tirzepatide.

  • Compounded oral tirzepatide
  • $167–$229 range per dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

The Prescriber's Perspective

Writing personalization notes takes prescribers time, and time is billed. Some platforms have absorbed the additional documentation burden into existing consult fees. Others have added a small fee for compounded prescriptions specifically. Either way, the additional documentation is now standard practice at well-run platforms — a pattern you should expect and welcome.

Where to Start

Embody

Injectable semaglutide — pricing varies

Injectable semaglutide only; a lead compounded-injectable option.

  • Injectable semaglutide focus
  • Standard 12-week titration
  • Direct-to-patient pharmacy shipping
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

MadeMed

Oral tirzepatide ~$229/mo

Independent compounder offering compounded oral tirzepatide.

  • Compounded oral tirzepatide
  • $167–$229 range per dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

SHED

Starts lower, $399/mo at 7.5mg+

Note: SHED's price jumps to $399/mo once you titrate to 7.5mg or higher.

  • Lower entry pricing
  • Price jump at 7.5mg+
  • Compounded semaglutide + tirzepatide
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →